SCHEMBL19253323

SCHEMBL19253323

Cc1cc(N)c(C(=O)c2ccccc2)cc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.53
GAA P10253 1/20 0.53
POLB P06746 2/20 0.50
MAPK14 Q16539 2/20 0.49
MAPK13 O15264 1/20 0.49
MAPK12 P53778 1/20 0.49
MAPK11 Q15759 1/20 0.49
ALDH1A1 P00352 2/20 0.49
CD44 P16070 1/20 0.47
ALOX15 P16050 2/20 0.47
LMNA P02545 3/20 0.44
MEN1 O00255 1/20 0.44
USP2 O75604 1/20 0.44
GLA P06280 1/20 0.44
KMT2A Q03164 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PBRM1 Q86U86 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11117347 0.86 MAPT (0.60) MAPTGAAPOLBMAPK14ALDH1A1
SCHEMBL11215128 0.86 MAPT (0.60) MAPTGAAPOLBMAPK14MAPK13
SCHEMBL10248660 0.86 CHRM4 (0.44) MAPTPOLBALDH1A1CD44LMNA
SCHEMBL3664055 0.83 MAPT (0.54) MAPTGAAALDH1A1LMNAMEN1
SCHEMBL9061252 0.81 ALDH1A1 (0.58) MAPTGAAPOLBMAPK14MAPK13
SCHEMBL12304995 0.81 PTGS1 (0.45) MAPTGAAPOLBALDH1A1LMNA
SCHEMBL5533149 0.80 CD44 (0.56) MAPTGAAPOLBALDH1A1CD44
SCHEMBL14916456 0.80 MAPT (0.53) MAPTGAAPOLBMAPK14MAPK13
SCHEMBL6055735 0.80 MAPT (0.54) MAPTGAAALDH1A1LMNAMEN1
SCHEMBL8033801 0.80 MAPT (0.72) MAPTGAAPOLBMAPK14MAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3419961-B1 UV/VISIBLE-ABSORBING VINYLIC MONOMERS AND USES THEREOF ALCON INC (CH) 2020-09-02 EP disclosed
US-10268053-B2 UV/visible-absorbing vinylic monomers and uses thereof NOVARTIS AG (CH) 2019-04-23 US disclosed
EP-3419961-A1 UV/VISIBLE-ABSORBING VINYLIC MONOMERS AND USES THEREOF Novartis AG (CH) 2019-01-02 EP disclosed
WO-2017145022-A1 UV/VISIBLE-ABSORBING VINYLIC MONOMERS AND USES THEREOF NOVARTIS AG (CH) 2017-08-31 WO disclosed
US-20170242274-A1 UV/VISIBLE-ABSORBING VINYLIC MONOMERS AND USES THEREOF ALCON INC. (CH) 2017-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10268053-B2 UV/visible-absorbing vinylic monomers and uses thereof VCL, UACA, XRCC6 MAPT 132/4885GAA 2532/4885POLB 2981/4885
US-20170242274-A1 UV/VISIBLE-ABSORBING VINYLIC MONOMERS AND USES THEREOF VCL, UACA, XRCC6 MAPT 132/4885GAA 2532/4885POLB 2981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.